(Total Views: 452)
Posted On: 05/16/2025 8:31:19 AM
Post# of 154977
Quote:
Probably a silly question but can CTC's express different levels of PD-L1 compared with those in the TME? The maraviroc results are from tumor specimens.
With leronlimab and to a lesser extent maraviroc the locus of increased macrophage activity will be the tumor, metastasis sites and the TME. Which is where I would expect the greatest amount of PD-L1 activation. CTCs originate from the original tumor and metastasis so I wouldn't expect a greatly differing percentage in CTCs.
(9)
(0)
